// App-Quantinova.ai

: Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Naïve Chronic Lymphocytic Leukemia

Researchers

Presenter

  • Ariel Felipe Grajales-Cruz

Principal Investigators

  • Julio C. Chavez

  • Elyce P. Turba

  • Lisa Nodzon

  • Francisco Perez Leal

  • Jose Sandoval-Sus

  • Rami S. Komrokji

  • Frederick L. Locke

  • Mohamed A Kharfan-Dabaja

  • Bijal D. Shah

  • Lubomir Sokol

  • Celeste M. Bello

  • Javier Pinilla Ibarz

Medical Centers

  • Moffitt Cancer Ctr Univ of S Florida, Tampa, FL

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • Malignant Hematology, Moffitt Cancer Center, Tampa, FL

  • Hematology,H. U. san Pedro de Alcantara,Caceres,Spagna

  • Moffitt Cancer Center, Tampa, FL

  • Department of Blood and Marrow Transplantation, Clinical Division, Moffitt Cancer Center, Tampa, FL

  • Division of Hematology & Medical Oncology, Mayo Clinic, Jacksonville, FL

  • Moffitt Cancer Center, Tampa, FL

  • Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

Locations

  • United States

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Oncology (ONC)

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic Lymphocytic Leukemia

  • Tumor lysis syndrome

  • Venous thrombosis

Biomarkers

  • RNA-binding protein FUS/TLS

Drug/Treatment

  • Trimethoprim/sulfamethoxazole

  • Methylprednisolone

  • Lenalidomide

  • Trimethoprim

  • Allopurinol

  • Fluconazole

  • ofatumumab Intravenous

  • Acyclovir

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • Single Center

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved